Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport®) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-r1sistant neurogenic detrusor overactivity

International Urology and Nephrology

Volumn 41, Issue 4, 2009, Pages 805-813

  Ghalayini, Ibrahim Fathi ^a   Mohammed A Al Ghazo, ^a   Elnasser, Ziad Ali ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Botulinum toxin Neurogenic detrusor overactivity Treatment outcome.

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADULT; ARTICLE; BLADDER COMPLIANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOMETRY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PATIENT SATISFACTION; RELAPSE; REPEATED DRUG DOSE; THERAPY RESISTANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URODYNAMICS;

ADOLESCENT; ADULT; BOTULINUM TOXIN TYPE A; CHOLINERGIC ANTAGONISTS; COHORT STUDIES; CYSTOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS; YOUNG ADULT;

EID: 77954563892     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-009-9528-y     Document Type: Article

References (28)

1. Leippold T, Reitz A, Schurch B (2003) Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44:165-174. doi:10.1016/S0302-2838(03)00250-1 (Pubitemid 36916999)
2. Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176:177-185. doi:10.1016/S0022-5347(06)00590-8
3. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) Comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984-989. doi:10.1097/01.ju. 0000169480.43557.31 (Pubitemid 41140656)
4. Ghalayini IF, Al-Ghazo MA (2007) Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 26:531-536. doi:10.1002/nau.20403 (Pubitemid 47036140)
5. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in treatment of painful bladder syndrome: a pilot study. Eur Urol 49:704-709. doi:10.1016/j.eururo.2005.12.002
6. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CG, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528-535. doi:10.1016/j.eururo.2005.12.012 (Pubitemid 43259564)
7. Patki PS, Hamid R, Arumugam K, Shah PJR, Craggs M (2006) Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 98:77-82. doi:10.1111/j.1464-410X.2006.06192.x (Pubitemid 43885510)
8. Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653-659. doi:10.1016/j.eururo.2004. 11.009 (Pubitemid 40521915)
9. Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P (2006) What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97:1030-1034. doi:10.1111/j.1464-410X.2006.06091.x
10. Odergren T, Hjaltason H, Kaakkola S et al (1998) A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6-12. doi:10.1136/jnnp.64.1.6
11. Schäfer W, Abrams P, Liao L et al (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21:261-274. doi:10.1002/nau.10066 (Pubitemid 34411846)
12. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692-697. doi:10.1016/S0022-5347(05)67283-7
13. Barinaga M (1993) Secrets of secretion revealed. Science 260:487-489. doi:10.1126/science.8475382
14. Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E (2006) Histologic features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50:1058-1064. doi:10.1016/j.eururo.2006.01.025 (Pubitemid 44486475)
15. Schurch B, de Seze M, Denys P et al (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196-200. doi:10.1097/01.ju.00001620 35.73977.1c
16. Grosse J, Kramer G, Tong TQT, Stohrer M, Jakse G (2005) Efficacy, dosage and safety of Dysport English botulinum toxin A in severe neurogenic detrusor overactivity NDO. Eur Urol Suppl 4:405
17. Del Popolo G, Filocamo MT, Marzi VL et al (2008) Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 53:1013-1020. doi:10.1016/j.eururo. 2007.09.034
18. Holds JB, AldersonK,Fogg SG, Anderson RL(1990) Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Ophthalmol Vis Sci 31:964-967
19. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155:1023-1029. doi:10.1016/S0022-5347(01)66376-6 (Pubitemid 26052703)
20. Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510-515. doi:10.1016/j.eururo.2003.12.004 (Pubitemid 38376219)
21. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E (2007) Do repeat intradetrusor botu-linum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 52:1729-1735. doi:10.1016/j.eururo. 2007.08.052 (Pubitemid 350064538)
22. Haferkamp A, Schurch B, Reitz A et al (2004) Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 46:784-791. doi:10.1016/j.eururo.2004. 07.011 (Pubitemid 39488414)
23. Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in sub-urothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977-982. doi:10.1097/01.ju.0000169481.42259. 54 discussion 982-983
24. Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644-650. doi:10.1016/j.eururo.2005.12.010 (Pubitemid 43374724)
25. Borodic GE, Ferrante R (1992) Effects of repeated botu-linum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 12:121-127
26. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68:1193-1197. doi:10.1016/j.urology.2006.08.1069 (Pubitemid 44880353)
27. Giannantoni A, Mearini E, Di Stasi SM et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56:79-87
28. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH (2003) Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44:139-143. doi:10.1016/S0302-2838(03)00136-2 (Pubitemid 36741389)